Skip to content
FDA Import Alert · 66-40

Shimoga Chemicals · Sangli, INDIA

Listed 2026-06-02 · 15 product codes · Source: FDA Import Alert 66-40 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

Shimoga Chemicals

13 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2026-07-21 ~ 2026-10-23

Areas cited

Process validationDeviation, CAPA, and investigationData integrityDocumentation and recordsValidation and qualificationEquipment and facilityLaboratory and QC controlsStability and storageQuality unit oversight

Published inspection documents

Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP. Investigation Handling Your QU failed to ensure that discrepancies and potential OOS events were adequately investigated. Your firm has manufactured and distributed approximately (b)(4) batches since April 2023. While your firm has not documented any OOS investigations, out-of-trend investigations, or laboratory incidents over at least the last two years, during the inspection, our investigators identified multiple events that should have triggered formal investigations, including the unreported OOS assay result for batch CC/005/24-25. Without adequate investigations, quality failure may go undetected and unresolved. Your response is inadequate. While you acknowledge discrepancies and potential OOS events were not adequately investigated, you do not provide a commitment to conduct any formal OOS investigation for batch CC/005/24-25. Stability Program Deficiencies Your QU failed to ensure that stability data adequately supports the assigned (b)(4) expiry date for clomiphene citrate USP. Your firm lacked raw test data, electronic or hardcopy, to support the results of your long-term stability study. In addition, while your stability management procedure requires that at least one commercial batch be placed on stability annually, your firm only placed batches on stability in 2021, 2022, and 2023. Your firm failed to place any U.S. batches manufactured in 2025 and 2026 on stability. Further, stability samples were stored in packaging that differed from the commercial container-closure system. This packaging has not been evaluated for equivalence. Without complete stability data, there is no assurance that the API will maintain all quality attributes through expiry. Your response is inadequate. You state that the ongoing stability study continues, but you fail to address the absence of raw data from the foundational 2015 study or your failure to place commercial batches on stability annually, as required by your own procedure. CGMP Training Concerns Your QU failed to ensure that manufacturing personnel were adequately trained. For example, an analyst who performed unreported injections lacked documented laboratory training and CGMP training. Additionally, no training records were available for a production operator who performed (b)(4) operations on a batch in U.S. distribution. Using untrained personnel may create a systemic risk, potentially resulting in quality failures. Your response is inadequate. You acknowledge the use of untrained or insufficiently trained personnel, but you provide only a general commitment to retraining. This commitment lacks a specific, documented training matrix, a training schedule, or qualification criteria for affected personnel. In response to this letter, provide: A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to: o A determination of whether procedures used by your firm are robust and appropriate o Provisions for QU oversight throughout your operations, to evaluate adherence to appropriate practices o A complete and final review of each batch and its related information before the QU disposition decision o Oversight and approval of investigations and discharging of all other QU duties, to ensure identity, strength, quality, and purity of all products A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to: o Stability-indicating methods o Stability studies for each drug product in its marketed container-closure system before distribution is permitted Position descriptions that outline defined qualifications for key personnel, particularly within the QU, to confirm appropriate assignment of responsibilities. Evidence that trained skills are being applied in day-to-day operations, including any managerial oversight mechanisms used to verify on-the-job performance. Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https://www.fda.gov/media/71023/download, Q9(R1) Quality Risk Management https://www.fda.gov/media/167721/download, and ICH Q10 Pharmaceutical Quality System at https://www.fda.gov/media/71553/download. Data Integrity Remediation Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA's guidance document Data Integrity and Compliance With Drug CGMP : Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https://www.fda.gov/media/119267/download. We acknowledge your commitment to engaging an independent third-party data integrity consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide: A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include: o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude. o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third-party. o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility's operations in which you discovered data integrity deficiencies. o A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third-party with specific expertise in the area where potential breaches were identified should evaluate all occurrences. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations. A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include: o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate, including analytical data, manufacturing records, and all data submitted to FDA. o A comprehensive description of the root causes of your data integrity lapses, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm. o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, and enhanced complaint monitoring. o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company's data. o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol. o Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by an independent quality assurance function, along with expertise from outside entities whenever needed). A status report for any of the above activities already underway or completed. Drug Recall On May 14, 2026, you issued a voluntary recall of clomiphene citrate USP due to deficiencies with your quality system and data integrity concerns. The company announcement was posted to the FDA website: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=221115. Additional API CGMP Guidance FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https://www.fda.gov/media/71518/download. CGMP Consultant Recommended Based upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm's compliance status with FDA. Your use of a consultant does not relieve your firm's obligation to comply with CGMP. Your firm's executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. 2026-07-21 US FDA 3 findingsDeviation, CAPA, and investigation · Process validation and 1 more View the regulator's official source

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Shimoga Chemicals — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.